Boehringer Ingelheim International GmbH Company Profile

05:39 EDT 18th June 2018 | BioPortfolio





Phone: 49-6132-77-0
Fax: 49-6132-77-3000

News Articles [678 Associated News Articles listed on BioPortfolio]

Boehringer Ingelheim i Uniwersytet Vanderbilt poszerzają współpracę w celu opracowania ...

-- Trzecia współpraca firmy Boehringer Ingelheim i Uniwersytetu Vanderbilt INGELHEIM, Niemcy i NASHVILLE, Tennessee, 13 marca 2018 r. /PRNewswire/ -- Koncern Boehringer Ingelheim i Read more...

Spoločnosť Boehringer Ingelheim a Univerzita Vanderbilt rozširujú svoje partnerstvo s ...

-- Ide už o tretiu spoluprácu medzi spoločnosťou Boehringer Ingelheim a Univerzitou Vanderbilt INGELHEIM, Nemecko a NASHVILLE, Tennessee, 13. marca 2018 /PRNewswire/ -- Spoločnosť Boehring...

Boehringer Ingelheim Doubles its Venture Fund for Exciting Biotech

Boehringer Ingelheim has committed to continue helping young companies grow by doubling the size of its venture fund to €250M, which will allow it to expand its focus. Boehringer Ingelheim is a big...

Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 17022018] Prices from USD $350

Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and In...

No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug

Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of German...

Topas Therapeutics GmbH: Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license sever...

New Indication For Boehringer Ingelheim's Gilotrif Okayed By FDA

NewsThe FDA approved a supplemental New Drug Application for Boehringer Ingelheim's Gilotrif for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have non-...

Boehringer Ingelheim Strikes a Series of Investments and Collaborations Worldwide

The last week has marked plenty of investment activity in operations, collaborations and PR the last week or two for Ingelheim, Germany-based Boehringer Ingelheim.

Drugs and Medications [508 Associated Drugs and Medications listed on BioPortfolio]

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Dulcolax balance [Boehringer Ingelheim Pharmaceuticals Inc]

Boehringer-Ingelheim Consumer Health Care Products Dulcolax Balance® Drug Facts

Pradaxa [Boehringer Ingelheim Pharmaceuticals Inc.]

These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA. PRADAXA® (dabigatran etexilate mesylate) capsules for o...

PubMed Articles [539 Associated PubMed Articles listed on BioPortfolio]

Boehringer-Ingelheim Satellite Symposium Choosing the Right Controller Therapy in Pediatric Patients with Asthma.

Donated chemical probes for open science.

Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality ...

Correction to: Lonoctocog Alfa: A Review in Haemophilia A.

The article Lonoctocog Alfa: A Review in Haemophilia A, written by Zaina T. Al-Salama and Lesley J. Scott, was originally published Online First without open access. After publication in volume 77...

Mycobacterium Interjectum isolated from an immunocompetent host with lung infection.

Improved molecular diagnostic techniques have resulted in increased reporting of nontuberculous mycobacterial infections. A 40-year-old male immunocompetent individual presented with cough and fever o...

Ocular Impression-Taking-Which Material Is Best?

To assess the efficacy and effect on clinical signs of a polyvinylsiloxane (Tresident; Shütz Dental Group GmbH, Germany) compared with an irreversible hydrocolloid (Orthoprint; Zhermack SpA, Badia Po...

Clinical Trials [1005 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH & Co. KG to Boehringer Ingelheim compared to ambroxol ...

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

This is a Phase IV multi-center, randomized, open-label, cross-over, placebo study in subjects with Chronic Obstructive Pulmonary Disease (COPD) to compare inhaler-specific preference attr...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fasting conditions using a sin...

Companies [1820 Associated Companies listed on BioPortfolio]

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim erforscht, entwickelt, produziert und vermarktet Arzneimittel für Menschen in aller Welt.Mit 37.406 Mitarbeitern, die in 143 Gesellschaften auf allen Kontinenten beschäftigt sin...

Boehringer Ingelheim Pharmaceuticals, Inc

Boehringer Ingelheim Corporation is the U.S. member of the Boehringer Ingelheim worldwide group of companies dedicated to the discovery, development, manufacture and marketing of innovative human and ...

Boehringer Ingelheim Limited

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146...

Boehringer Ingelheim Pharmaceuticals Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group ...

Boehringer Ingelheim Pharmaceuticals, Inc.

Metabolism is one of Boehringer Ingelheim's core R&D areas and diabetes is one of the indications at the center of interest within the company's global research network. Boehringer Ingelheim is commit...

More Information about "Boehringer Ingelheim International GmbH" on BioPortfolio

We have published hundreds of Boehringer Ingelheim International GmbH news stories on BioPortfolio along with dozens of Boehringer Ingelheim International GmbH Clinical Trials and PubMed Articles about Boehringer Ingelheim International GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Boehringer Ingelheim International GmbH Companies in our database. You can also find out about relevant Boehringer Ingelheim International GmbH Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record